Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01587079 · ClinicalTrials.gov registry record · Phase 2
Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT01587079 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 159 participants.
The verdict
NCT01587079, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate to severe COPD
Interventions
- DRUG PT003
- DRUG PT001
- DRUG PT005
- DRUG Tiotropium inhalation powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01587079
The ClinicalTrials.gov registry entry for NCT01587079 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PT003 is the first listed.
NCT01587079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01587079 about?
NCT01587079 is a clinical study titled "Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease". The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate to severe COPD
What is the current status of trial NCT01587079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2012-04. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01587079?
The interventions under investigation include: PT003 (DRUG), PT001 (DRUG), PT005 (DRUG), Tiotropium inhalation powder (DRUG).
Who is sponsoring clinical trial NCT01587079?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.